• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.59% Nasdaq Up1.89%

    Ophthotech Corporation (OPHT)

    51.97 Up 0.29(0.56%) 3:51PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Ophthotech Corporation
    One Penn Plaza
    19th Floor
    New York, NY 10119
    United States - Map
    Phone: 212-845-8200
    Fax: 212-845-8250
    Website: http://www.ophthotech.com

    Index Membership:N/A
    Full Time Employees:130

    Business Summary 

    Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ophthotech Corporation

    Corporate Governance 
    Ophthotech Corporation’s ISS Governance QuickScore as of Jun 1, 2016 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 8; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. David R. Guyer M.D., 56
    Chairman and Chief Exec. Officer
    Dr. Samir C. Patel M.D., 55
    Co-Founder, Vice Chairman and Pres
    Mr. Glenn P. Sblendorio MBA, 60
    Chief Financial Officer, Chief Operating Officer, Exec. VP and Treasurer
    Ms. Barbara A. Wood Esq., 53
    Sr. VP, Gen. Counsel and Sec.
    Mr. Henric Bjorn Bjarke , 49
    Chief Commercial Officer and Sr. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders